Provided by Tiger Trade Technology Pte. Ltd.

Neumora Therapeutics, Inc.

2.49
-0.0100-0.40%
Pre-market: 2.570.0800+3.21%08:00 EDT
Volume:1.12M
Turnover:2.83M
Market Cap:423.30M
PE:-1.70
High:2.61
Open:2.49
Low:2.45
Close:2.50
52wk High:3.65
52wk Low:0.6110
Shares:170.00M
Float Shares:86.06M
Volume Ratio:1.66
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4632
EPS(LYR):-1.5296
ROE:-104.35%
ROA:-56.71%
PB:3.20
PE(LYR):-1.63

Loading ...

Press Release: Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Dow Jones
·
Jan 05

Neumora Therapeutics Reports Positive Phase 1b Results for NMRA-511 in Alzheimer’s Agitation

Reuters
·
Jan 05

Neumora Therapeutics Announces Positive Results From Nmra-511 Phase 1B Signal-Seeking Study in Alzheimer’s Disease Agitation

THOMSON REUTERS
·
Jan 05

Neumora Therapeutics Inc - to Evaluate Higher Doses of Nmra-511 in 2026

THOMSON REUTERS
·
Jan 05

Neumora Therapeutics Inc - Nmra-511 Shows 15.7 Reduction on Mean Cmai Total Score

THOMSON REUTERS
·
Jan 05

Neumora Therapeutics Inc - Nmra-511 Shows Unsurpassed Effect Size in Elevated Anxiety Population

THOMSON REUTERS
·
Jan 05

Neumora Therapeutics Shares Rise After RBC Upgrade

MT Newswires Live
·
Dec 02, 2025

Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline

Benzinga
·
Dec 02, 2025

Neumora Therapeutics Raised to Outperform From Sector Perform by RBC Capital

Dow Jones
·
Dec 01, 2025

Shares of Neumora Therapeutics up 8% Premarket After RBC Raises to Outperform From Sector Perform

THOMSON REUTERS
·
Dec 01, 2025

RBC Upgrades Neumora Therapeutics to Outperform From Sector Perform, Raises Price Target to $7 From $4, Keeps Speculative Risk

MT Newswires Live
·
Dec 01, 2025

Neumora Therapeutics Inc : RBC Raises to Outperform From Sector Perform; Raises Target Price to $7 From $4

THOMSON REUTERS
·
Dec 01, 2025

Neumora Therapeutics Issues 2.85 Million Shares to K2 HealthVentures in Loan Conversion

Reuters
·
Nov 22, 2025

Neumora Therapeutics Officer Daljit Singh Aurora Reports Disposal of Common Shares

Reuters
·
Nov 14, 2025

H.C. Wainwright Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
Nov 10, 2025

13D Filings -- Barrons.com

Dow Jones
·
Nov 08, 2025

Analysts Are Neutral on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), ICU Medical (ICUI)

TIPRANKS
·
Nov 07, 2025

Neumora Therapeutics, Inc.: Promising Growth and Innovation with Key Developments in Alzheimer’s Treatment

TIPRANKS
·
Nov 07, 2025

Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Charles River Labs (CRL) and Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
Nov 07, 2025

Neumora Therapeutics Unveils Pipeline Advancements Targeting Major Brain Disorders

Reuters
·
Nov 06, 2025